In contrast, a large meta-analysis including 386 KRAS-mutant and 927 KRAS wild-type NSCLC patients saw significant improvements in overall and progression-free survival in KRAS-mutant NSCLC patients receiving ICIs in first or second-line with or without chemotherapy compared to chemotherapy alone and significantly longer overall survival in KRAS-mutant compared to KRAS wild-type NSCLC (48). This evidence concerns the gene KRAS and non-small cell lung carcinoma.